Cellectis (LTS:0WA2) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0WA2 Cellectis SA LTS:0WA2
50 GF Score
Price €2.66
GF Value €2.62
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis Short-term investments?

Short-term investments only applies to insurance companies.

LTS:0WA2
50GF Score
Cellectis SA LTS:0WA2
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (LTS:0WA2) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of €2.66 is trading 1.5% above its estimated GF Value™ of €2.62. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for LTS:0WA2:

  • Short-term investments:
  • GF Value™: €2.62 vs. price of €2.66 (1.5% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the LTS:0WA2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
50GF Score

Get the complete analysis for LTS:0WA2

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€2.62
GF Value